Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis
Authors:
- Daniela PuglieseDPDaniela Pugliese
- Silvio DaneseSDSilvio Danese
- Gianluca RizzoGRGianluca Rizzo
- Carla FeliceCarla Felice
- Manuela MarzoMMManuela Marzo
- Gianluca AndrisaniGAGianluca Andrisani
- Gionata FiorinoGFGionata Fiorino
- Olga Maria NardoneONOlga Maria Nardone
- Italo De VitisIVItalo De Vitis
- Alfredo PapaAPAlfredo Papa
- Gian Lodovico RapacciniGRGian Lodovico Rapaccini
- 1 August 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 20 (8) , 1368-1374
Abstract
Infliximab (IFX) has demonstrated effectiveness for inducing 12-month steroid-free clinical remission in patients with steroid-dependent ulcerative colitis (UC), but long-term data are lacking. The aim of the study was to describe the long-term outcome of IFX treatment in steroid-dependent UC and investigate if predictors of sustained clinical response and colectomy could be identified. Consecutive patients with steroid-dependent UC treated with IFX were studied. The coprimary prespecified outcomes were sustained clinical response in patients who achieved clinical remission or response after IFX induction and colectomy-free survival. Secondary analyses were addressed to look for predictors of sustained clinical response and colectomy. After induction, 76% (96/126) of patients achieved clinical benefit. The median duration of follow-up on IFX maintenance therapy was 41.5 months (interquartile range, 26-45). Sixty-four percent (46/96) of patients had sustained clinical response at median follow-up. Colectomy-free survival was 77% at median follow-up. Combination therapy of IFX with thiopurines was an independent predictor of sustained clinical response (P < 0.0001; hazard ratio [HR], 3.98; 95% confidence interval [CI], 1.73-9.14). Independent predictors of colectomy were Mayo endoscopic subscore of 3 at baseline (P = 0.04; HR, 2.77; 95% CI, 1.09-7.05) and high C-reactive protein after induction (P = 0.001; HR, 5.65; 95% CI, 2.03-15.7). Thiopurine naive status (P = 0.025; HR, 0.34; 95% CI, 0.13-0.87) was protective from colectomy. Long-term IFX treatment is effective in inducing sustained clinical response in patients with steroid-dependent UC. Combination therapy is predictive of sustained clinical response in the long-term. Patients with more severe endoscopic lesions at baseline and high C-reactive protein after induction are at higher risk of colectomy. Conversely, thiopurine naive status is protective from colectomy.Keywords
This publication has 20 references indexed in Scilit:
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative ColitisGastroenterology, 2014
- Infliximab in Steroid-dependent Ulcerative ColitisInflammatory Bowel Diseases, 2013
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current managementJournal of Crohn's and Colitis, 2012
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosisJournal of Crohn's and Colitis, 2012
- Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensusJournal of Crohn's and Colitis, 2012
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitisJournal of Crohn's and Colitis, 2009
- Long-term outcome after infliximab for refractory ulcerative colitisJournal of Crohn's and Colitis, 2008
- Predictors of early response to infliximab in patients with ulcerative colitisInflammatory Bowel Diseases, 2007
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987